Technology:
   Medarex Drug Trials Approved
The trials will be directed from the University of
Pittsburgh's medical school, and will include about 30 to 50
leukemia patients who have relapsed after treatment. Medarex
said acute myeloid leukemia afflicts about 11,000 new
patients a year in the U.S.